Clinical trial NCT00086190 - References

Depression — Study of Antidepressants in Parkinson's Disease

Citation(s)

•   Altamura AC, De Novellis F, Guercetti G, Invernizzi G, Percudani M, Montgomery SA
  Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res. 1989;9(6):391-6.
•   American Psychiatric Association
  Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, 1994.
•   Applebaum PS, Grisso T
  MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research. Sarasota, FL: Professional Resource Press, 2001.
•   Beck AT, Steer RA, Ball R, Ranieri W
  Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97.
•   Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F
  Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One. 2009;4(3):e4824. doi: 10.1371/journal.pone.0004824. Epub 2009 Mar 18. Review.
•   Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A
  Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990 Dec;51 Suppl B:28-33.
•   Conners C, Barkley R
  Rating scales and checklists for psychopharmacologic trials. Psychopharm Bull 1985;21:80-854.
•   Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destée A, Bordet R, Defebvre L
  Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008 Apr 30;23(6):850-7. doi: 10.1002/mds.21966.
•   Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R
  An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol. 1992 Mar;49(3):305-7.
•   Dubovsky S
  Geriatric Neuropsychopharmacology. In: Coffey C, Cummings J, eds. Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press, 1994:595-631.
•   Dunner DL, Cohn JB, Walshe T 3rd, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC Jr, et al
  Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry. 1992 Feb;53 Suppl:57-60.
•   Entsuah AR, Huang H, Thase ME
  Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001 Nov;62(11):869-77.
•   Fahn S, Elton RL
  Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information, 1992:153-163.
•   Feighner JP, Boyer WF, Meredith CH, Hendrickson G
  An overview of fluoxetine in geriatric depression. Br J Psychiatry Suppl. 1988 Sep;(3):105-8.
•   Folstein MF, Folstein SE, McHugh PR
  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.
•   Gentil V, Kerr-Correa F, Moreno R, D'Arrigo Busnello E, De Campos JA, Juruena MF, Lafer B, Moreno DH, De Cassia Rodrigues RL, Tiosso A, Benedictis E
  Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol. 2000 Mar;14(1):61-6.
•   Global Parkinson's Disease Survey Steering Committee
  Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002 Jan;17(1):60-7.
•   Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y
  A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl. 1989;350:132-4.
•   HAMILTON M
  A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.
•   Hirschfeld RM
  Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999 May;60(5):326-35. Review.
•   Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, Cabrera-Valdivia F, Alarcón J, García-Albea E
  Parkinsonism exacerbated by paroxetine. Neurology. 1994 Dec;44(12):2406.
•   Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK
  The quality of life in Parkinson's disease. Mov Disord. 2000 Mar;15(2):216-23.
•   Lachin JM
  Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93-113.
•   Little RJA, Rubin DB
  Statistical Analysis with Missing Data, Second Edition. Hoboken: John Wiley and Sons, 2002.
•   Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC
  The correlation of depression with functional activity in Parkinson's disease. J Neurol. 1997 Aug;244(8):493-8.
•   McDonald WM, Holtzheimer PE, Haber M, Vitek JL, McWhorter K, Delong M
  Validity of the 30-item geriatric depression scale in patients with Parkinson's disease. Mov Disord. 2006 Oct;21(10):1618-22.
•   Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A
  A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009 Mar 10;72(10):886-92. doi: 10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.
•   Montgomery SA, Asberg M
  A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9.
•   Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS, Robin DW, Gergel I, McCafferty J, Roose S
  Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999 Jul;156(7):1024-8.
•   Okun MS, Fernandez HH
  Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology. 2009 Mar 10;72(10):868-9. doi: 10.1212/01.wnl.0000338145.24512.02. Epub 2008 Dec 17.
•   Phillips P
  Keeping depression at bay helps patients with Parkinson disease. JAMA. 1999 Sep 22-29;282(12):1118-9.
•   Salzman C
  Pharmacologic treatment of depression in the elderly. J Clin Psychiatry. 1993 Feb;54 Suppl:23-8. Review.
•   Senn S, Julious S
  Measurement in clinical trials: a neglected issue for statisticians? Stat Med. 2009 Nov 20;28(26):3189-209. doi: 10.1002/sim.3603.
•   Simons JA
  Fluoxetine in Parkinson's disease. Mov Disord. 1996 Sep;11(5):581-2.
•   Spitzer RL, Gibbon M, Williams JBW
  Structured clinical interview for Axis I DSM-IV disorders: Biometrics Research Department. New York State Psychiatric Institute 1994.
•   Steur EN
  Increase of Parkinson disability after fluoxetine medication. Neurology. 1993 Jan;43(1):211-3.
•   Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC; Parkinson Study Group DATATOP Investigators
  Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009 Nov 3;73(18):1469-77. doi: 10.1212/WNL.0b013e3181bf992f.
•   Yeragani VK, Pesce V, Jayaraman A, Roose S
  Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002 Sep 1;52(5):418-29.
•   Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V
  Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46(3):125-35.
•   Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO
  Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49.

Study of Antidepressants in Parkinson's Disease

Details for clinical trial NCT00086190